| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut 06520-8020
Address all correspondence and requests for reprints to: Dr. Masiukiewicz , Section of Endocrinology, Yale University School of Medicine, P.O. Box 208020, 333 Cedar Street, FMP 109, New Haven, Connecticut 06520-8020. E-mail: urszula.masiukiewicz{at}yale.edu
Interleukin (IL)-6 promotes osteoclastogenesis and is thought to play a role in the bone loss that follows estrogen withdrawal. In vitro studies have demonstrated that IL-6 is produced in response to PTH by cells in the osteoblast lineage and that PTH-induced bone resorption is inhibited by a neutralizing antibody to the IL-6 receptor. In addition, we have recently reported that IL-6 plays a role in PTH-induced bone resorption in humans with chronic PTH excess and in experimental animals during the short-term infusion of PTH. In the current study, we examined whether estrogen withdrawal augments PTH-induced IL-6 production. When cultured in the absence of estrogen, human osteosarcoma cells (Saos-2) treated with PTH demonstrated significantly greater release of IL-6 than cells grown under estrogen-replete conditions, 30-fold vs. 15-fold (P = 0.005). A similar effect but of lesser magnitude was seen with primary human osteoblasts. In vivo, PTH induced IL-6 production was also increased in the estrogen-deficient state (ovx) such that at the end of a 5-day PTH infusion, the mean circulating level of IL-6 was significantly higher in ovx vs. sham/ovx mice (60.1 vs. 16.9 pg/ml; P < 0.0001). The greater increase in circulating levels of IL-6 in PTH-treated ovx mice was paralleled by a greater rise in bone resorption markers with the mean level of urine collagen cross-links in the PTH-treated ovx group being more than 2.5-fold higher than in the PTH-treated sham/ovx animals (236 vs. 88.5 µg/mmol creatinine, P < 0.0001). Mean serum collagen cross-link values were 17.4 µg/liter in PTH-treated ovx vs. 7.4 µg/liter in PTH-treated sham/ovx animals (P < 0.0001). Treatment of animals with estrogen prevented the exaggerated response to PTH infusion such that the increase in both circulating levels of IL-6 and bone turnover markers in estrogen-treated animals were similar to those observed in sham/ovx animals and significantly lower than those in PTH-treated ovx animals. These findings may help to explain the increased skeletal sensitivity to the resorbing effects of PTH seen in the estrogen-deficient state.
This article has been cited by other articles:
 |
|
 |
|
  C. A. O'Brien, R. L. Jilka, Q. Fu, S. Stewart, R. S. Weinstein, and S. C. Manolagas IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E784 - E793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Iida-Klein, S S. Lu, R Kapadia, M Burkhart, A Moreno, D W Dempster, and R Lindsay Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice J. Endocrinol., September 1, 2005; 186(3): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nakanishi, K. Yoshioka, S. Joyama, N. Araki, A. Myoui, S. Ishiguro, T. Ueda, H. Yoshikawa, and K. Itoh Interleukin-6/Soluble Interleukin-6 Receptor Signaling Attenuates Proliferation and Invasion, and Induces Morphological Changes of a Newly Established Pleomorphic Malignant Fibrous Histiocytoma Cell Line Am. J. Pathol., August 1, 2004; 165(2): 471 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. VanHouten and J. J. Wysolmerski Low Estrogen and High Parathyroid Hormone-Related Peptide Levels Contribute to Accelerated Bone Resorption and Bone Loss in Lactating Mice Endocrinology, December 1, 2003; 144(12): 5521 - 5529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Nakchbandi, M. A. Mitnick, R. Lang, C. Gundberg, B. Kinder, and K. Insogna Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4946 - 4951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. S. Masiukiewicz, M. Mitnick, B. I. Gulanski, and K. L. Insogna Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2892 - 2898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pfeilschifter, R. Koditz, M. Pfohl, and H. Schatz Changes in Proinflammatory Cytokine Activity after Menopause Endocr. Rev., February 1, 2002; 23(1): 90 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-Y. Liu, P.-W. Wu, F. R. Bringhurst, and J.-T. Wang Estrogen Inhibition of PTH-Stimulated Osteoclast Formation and Attachment in Vitro: Involvement of Both PKA and PKC Endocrinology, February 1, 2002; 143(2): 627 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Nakchbandi, M. A. Mitnick, U. S. Masiukiewicz, B. h. Sun, and K. L. Insogna IL-6 Negatively Regulates IL-11 Production in Vitro and in Vivo Endocrinology, September 1, 2001; 142(9): 3850 - 3856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Z. Leder, M. R. Smith, M. A. Fallon, M.-L. T. Lee, and J. S. Finkelstein Effects of Gonadal Steroid Suppression on Skeletal Sensitivity to Parathyroid Hormone in Men J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 511 - 516. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
